By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Opioid analgesic > Tapentadol

Tapentadol

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|677 words

Tapentadol

What is Tapentadol?

Tapentadol is a centrally-acting opioid analgesic that belongs to the class of dual-action pain medications. It is prescribed for the management of moderate to severe acute and chronic pain conditions. Unlike traditional opioids, tapentadol combines opioid receptor activation with norepinephrine reuptake inhibition, offering a unique approach to pain relief.

Uses

Tapentadol is approved for several pain management indications:

Moderate to severe acute pain: Used for short-term pain relief following surgery, injury, or dental procedures when other pain medications are inadequate.

Chronic pain conditions: Prescribed for long-term management of persistent pain, particularly when continuous treatment is required and alternative options are insufficient.

Submit Your Paper
GMJ_Submit_Banner

Diabetic peripheral neuropathy: Extended-release formulations are used to treat nerve pain associated with diabetes that affects the hands and feet.

Post-surgical pain: Effective for managing pain following various surgical procedures, including orthopedic and abdominal surgeries.

Cancer-related pain: May be prescribed as part of comprehensive pain management in cancer patients requiring opioid therapy.

How it works

Tapentadol works through two distinct mechanisms to provide pain relief. It binds to mu-opioid receptors in the brain and spinal cord, similar to other opioid medications, while simultaneously blocking the reuptake of norepinephrine, a neurotransmitter involved in pain signaling. This dual action allows for effective pain control potentially with fewer opioid-related side effects compared to traditional opioids.

Side effects

Common side effects include:

  • Nausea and vomiting
  • Dizziness and drowsiness
  • Constipation
  • Headache
  • Dry mouth
  • Fatigue and weakness
  • Loss of appetite
  • Sweating

Serious side effects requiring immediate medical attention:

  • Severe respiratory depression or difficulty breathing
  • Allergic reactions including rash, swelling, or severe itching
  • Seizures or convulsions
  • Signs of serotonin syndrome (confusion, rapid heart rate, high fever)
  • Severe low blood pressure or fainting

Warnings and precautions

Tapentadol carries several important safety considerations. Patients with respiratory conditions such as severe asthma, chronic obstructive pulmonary disease, or sleep apnea should avoid this medication due to the risk of respiratory depression. The drug has significant potential for abuse, addiction, and dependence, requiring careful monitoring and gradual dose reduction when discontinuing. Individuals with a history of head injury, brain tumors, or increased intracranial pressure should use tapentadol with extreme caution. Pregnant women should only use this medication when potential benefits outweigh risks, as it may cause withdrawal symptoms in newborns. Patients with severe liver or kidney impairment may require dose adjustments or should avoid the medication entirely, as these organs are responsible for processing and eliminating the drug from the body.

Interactions

Tapentadol can interact with numerous medications, potentially causing dangerous effects:

Monoamine oxidase inhibitors (MAOIs): Can cause serotonin syndrome, a potentially life-threatening condition involving confusion, rapid heart rate, and high fever.

Serotonergic medications: Including SSRIs, SNRIs, and triptans, may increase the risk of serotonin syndrome when combined with tapentadol.

Central nervous system depressants: Benzodiazepines, alcohol, and other opioids can enhance sedation and respiratory depression effects.

Anticholinergic medications: May increase the risk of constipation, urinary retention, and other anticholinergic effects.

CYP2D6 inhibitors: Medications like fluoxetine and paroxetine can affect tapentadol metabolism and increase side effects.

Blood pressure medications: Tapentadol may enhance the hypotensive effects of antihypertensive drugs.

Seizure threshold-lowering drugs: May increase the risk of seizures when used with tapentadol.

Muscle relaxants: Can increase drowsiness and respiratory depression when combined with tapentadol.

Check interactions with the GMJ Interaction Checker

Dosage

Tapentadol dosage varies based on the formulation and individual patient needs. For immediate-release tablets treating acute pain, the typical starting dose is 50 to 100 mg every 4 to 6 hours as needed, with a maximum of 600 mg per day. Extended-release formulations for chronic pain typically start at 50 mg twice daily, with potential increases to a maximum of 250 mg twice daily based on pain relief and tolerance. Elderly patients and those with liver or kidney impairment may require lower starting doses. Dosage should always be individualized and determined by a healthcare provider based on pain severity, patient response, and risk factors.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Tapentadol." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/tapentadol/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
UK Health Security Agency Issues Updated Hantavirus Guidance as Rare Disease Remains Critical Health Concern

UK Health Security Agency updates hantavirus guidance, emphasising continued surveillance for rare…

Cosmeticorexia: How Social Media Drives Children’s Obsessive Skincare Behaviour

Mental health experts identify "cosmeticorexia" as children as young as 8 develop…

Global Temperatures Likely to Set Records Over Next Five Years, WMO Warns

Global temperatures are likely to reach record levels in the next five…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Meperidine

By
Prof. Giorgi Pkhakadze
02/06/2026

Hydrocodone

By
Prof. Giorgi Pkhakadze
02/06/2026

Fentanyl

By
Prof. Giorgi Pkhakadze
02/06/2026

Codeine

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up